Real-world (RW) outcomes of newly diagnosed multiple myeloma (NDMM) patients (pts) treated with front-line daratumumab (dara), bortezomib (bor), lenalidomide (len) and dexamethasone (dex) (DVRd)
Year: 2025
Type: conference-abstract
Source: Blood
Authors: Ricardo Parrondo, Ricardo de Menezes, Hanna Sledge, Kanika Yadav, Madhavi Nayyar, P. Leif Bergsagel, Rafael Fonseca, Prashant Kapoor, Francis Buadi, Morie Gertz, Angela Dispenzieri, Vivek Roy, Taimur Sher, Moritz Binder, Nadine Abdallah, Saurabh Chhabra, S. Vincent Rajkumar, Wilson Gonsalves, Joselle Cook, David Dingli, Yi Lin, Eli Muchtar, Caitlin Flott, Udit Yadav, Rahma Warsame, J Wiedmeier-Nutor, Taxiarchis Kourelis, Nelson Leung, Mustaqeem Siddiqui, Andre Fernandez, Shaji Kumar, Asher Chanan-Khan, Sikander Ailawadhi
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4417022437
Cites:
Cited by:
Related to: